Condition: Any Solid Oral Medication · Sponsor: Dosentrx Ltd.
Primary Objective: • To assess the persistence of ReX technology platform use, measured by the percentage (%) of participants who used ReX: 1) throughout the study period and 2) before the treatment discontinuation. Secondary Objective: • To evaluate the impact of the ReX technology platform on ribo treatment duration and ribo dose taking adherence as compared to control group.
This description comes directly from the study's public registry record.
Mark Summers · +1 612 817 0959 · msummers@dosentrx.com
Always discuss trial participation with your own doctor first.
| Allina | Minneapolis, Minnesota, United States | Recruiting |
| Texas Oncology | Austin, Texas, United States | Recruiting |
| Virginia Cancer Center | Richmond, Virginia, United States | Recruiting |
| Lumicera | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06344416